Peptide Research
Eloralintide + Tirzepatide: Why the Obesity Research Community Is Suddenly Paying Close Attention
Why researchers are paying close attention to one of the most intriguing investigational obesity combinations currently under development. Last Updated:
Petrelintide: The Next Generation Amylin-Based Weight Loss Drug Reshaping Obesity Treatment in 2026
The obesity treatment landscape has undergone a dramatic transformation over the past several years. Medications such as semaglutide and tirzepatide
Myostatin Inhibitors and GLP-1 Therapy: The Future of Fat Loss, Muscle Preservation, and Next-Generation Obesity Treatment
Introduction: The Next Evolution of Weight Loss Has Arrived The obesity-treatment landscape has changed dramatically over the past few years.
Brenipatide (LY3537031): The Next-Generation GLP-1 Peptide Being Studied for Weight Loss, Alcohol Cravings, and Addiction Research
What Is Brenipatide and Why Is Everyone Suddenly Talking About It? A decade ago, very few people outside endocrinology had
Eloralintide + Tirzepatide Data at ADA 2026 May Signal the Future of Obesity Treatment
New Data Presented at the American Diabetes Association’s 86th Scientific Sessions Suggest Amylin and Incretin Combination Therapy Could Become a
Eloralintide vs Retatrutide: Which Obesity Compound Has Bigger Long-Term Potential?
For the past several years, obesity research has been dominated by incretin-based therapies. First came GLP-1 receptor agonists. Then dual